Fiche centre
Clinical Research Institute
Los Angeles — United States
Essais liés8clinical trials
VilleLos Angeleslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04437511
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Dihydroergotamine | Migraine | Phase 3 | NCT04406649 | ASCEND — A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine | COMPLETED |
| Dihydroergotamine | Migraine | Phase 3 | NCT04940390 | SUMMIT — A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine | COMPLETED |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| Rimegepant | Migraine | Phase 4 | NCT07609914 | A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Atogepant 60 mg | Migraine | Phase 4 | NCT06972056 | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | RECRUITING |